SynthesisThoracic cancer2021
Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta-analysis update.
Synthesis in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta-analysis.Cancer cytopathology · 2025Pooled it
- Meta-analysis of the accuracy for RASSF1A methylation in bronchial aspirates for the diagnosis of lung cancer.PloS one · 2024Pooled it
- Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta-analysis update.Thoracic cancer · 2021Pooled it
- The advances of DNA methylation in the liquid biopsy for the detection of lung cancer.Frontiers in oncology · 2025Review
- Identifying targeted cell-free DNA methylation regions in head and neck cancer via paired methylome analysis.Research square · 2024Article
- Plasma DNA methylation detection for early screening, diagnosis, and monitoring of esophageal adenocarcinoma and squamous cell carcinoma.World journal of gastroenterology · 2024Article
- Novel Semi-Nested Real-Time PCR Assay Leveraging Extendable Blocking Probes for ImprovedBiomolecules · 2024Article
- Evaluation of DNA methylation levels ofOncology reports · 2024Article
- Article
- Diagnostic value of SHOX2, RASSF1A gene methylation combined with CEA level detection in malignant pleural effusion.BMC pulmonary medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic performance of short state homeobox 2 (SHOX2) promoter methylation as biomarker for lung cancer identification through aggregating the open published data.
methodsWe did an electronic search in Pubmed, EMBASE, Ovid, Web of Science, Google Scholar, and the China National Knowledge Infrastructure (CNKI) to identify the publications related to SHOX2 promoter methylation and lung cancer. The diagnostic performance of sensitivity (SEN), specificity (SPE), odds ratio (DOR), and summary receiver operating characteristic (SROC) cure were aggregated by fixed or random effect model. Fagan's nomogram was used to investigate the post-test diagnostic probability. Deek's funnel plot and line regression test was applied to evaluate the publication bias.
resultsIn total, 18 clinical studies about SHOX2 promoter methylation and lung cancer were included in the meta-analysis. The combined diagnostic SEN, SPE, DOR were 0.63 (95% CI = 0.54-0.70), 0.91 (95% CI = 0.87-0.94), and 16.84 (95% CI = 11.18-25.36) in random effect model respectively. The pooled area under the curve (AUC) of SROC was 0.88 (95% CI = 0.84-0.90). The post-test probability of lung cancer was 88% and 29% when SHOX2 methylated and unmethylated in humoral components given a pre-test probability of 50%. Deek's funnel plot and regression test indicated no publication bias (p = 0.62).
conclusionSHOX2 promoter methylation in humoral components may be a potential biomarker for lung cancer diagnosis with relative high diagnostic specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.